NCT00121264View on ClinicalTrials.gov

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

sorafenib tosylate

Given orally

DRUG

tanespimycin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

PROCEDURE

magnetic resonance imaging

Correlative studies

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00121264 - 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter